Idiopathic intracranial hypertension: consensus guidelines on management by Mollan, SP et al.
 
 
Idiopathic intracranial hypertension: consensus
guidelines on management
Mollan, SP; Davis, B; Silver, NC; Shaw, S; Malucci, C; Wakerley, BR; Krishnan, A; Chavda,
S; Ramalingam, Satheesh; Edwards, J; Hemmings, K; Williamson, M; Burdon, MA; Hassan-
Smith, Zaki; Digre, K; Liu, GT; Jensen, R; Sinclair, Alexandra
DOI:
10.1136/jnnp-2017-317440
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Mollan, SP, Davis, B, Silver, NC, Shaw, S, Malucci, C, Wakerley, BR, Krishnan, A, Chavda, S, Ramalingam, S,
Edwards, J, Hemmings, K, Williamson, M, Burdon, MA, Hassan-Smith, Z, Digre, K, Liu, GT, Jensen, R &
Sinclair, A 2018, 'Idiopathic intracranial hypertension: consensus guidelines on management', Journal of
Neurology Neurosurgery and Psychiatry, vol. 89, pp. 1088-1100. https://doi.org/10.1136/jnnp-2017-317440
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1088 Mollan SP, et al. J Neurol Neurosurg Psychiatry 2018;89:1088–1100. doi:10.1136/jnnp-2017-317440
Review
Idiopathic intracranial hypertension: consensus 
guidelines on management
Susan P Mollan,1,2 Brendan Davies,3 Nick C Silver,4 Simon Shaw,5 Conor L Mallucci,6,7 
Benjamin R wakerley,8,9 Anita Krishnan,4 Swarupsinh v Chavda,10 
Satheesh Ramalingam,10 Julie edwards,11,12 Krystal Hemmings,13 
Michelle williamson,13 Michael A Burdon,2 Ghaniah Hassan-Smith,1,12 
Kathleen Digre,14 Grant T Liu,15 Rigmor Højland Jensen,16 Alexandra J Sinclair1,2,12,17
General neurology
To cite: Mollan SP, Davies B, 
Silver NC, et al. J Neurol 
Neurosurg Psychiatry 
2018;89:1088–1100.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
jnnp- 2017- 317440).
For numbered affiliations see 
end of article.
Correspondence to
Dr Alexandra J Sinclair, 
Metabolic Neurology, institute 
of Metabolism and Systems 
Research, University of 
Birmingham, Birmingham B15 
2TT, UK;  a. b. sinclair@ bham. 
ac. uk
Received 12 November 2017
Revised 6 February 2018
Accepted 7 February 2018
Published Online First 
14 June 2018
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY. 
Published by BMJ.
AbsTrACT
The aim was to capture interdisciplinary expertise from a 
large group of clinicians, reflecting practice from across 
the UK and further, to inform subsequent development of 
a national consensus guidance for optimal management 
of idiopathic intracranial hypertension (iiH).
Methods Between September 2015 and October 
2017, a specialist interest group including neurology, 
neurosurgery, neuroradiology, ophthalmology, nursing, 
primary care doctors and patient representatives 
met. An initial UK survey of attitudes and practice 
in iiH was sent to a wide group of physicians and 
surgeons who investigate and manage iiH regularly. 
A comprehensive systematic literature review was 
performed to assemble the foundations of the 
statements. An international panel along with four 
national professional bodies, namely the Association of 
British Neurologists, British Association for the Study of 
Headache, the Society of British Neurological Surgeons 
and the Royal College of Ophthalmologists critically 
reviewed the statements.
results Over 20 questions were constructed: one based 
on the diagnostic principles for optimal investigation 
of papilloedema and 21 for the management of iiH. 
Three main principles were identified: (1) to treat the 
underlying disease; (2) to protect the vision; and (3) to 
minimise the headache morbidity. Statements presented 
provide insight to uncertainties in iiH where research 
opportunities exist.
Conclusions in collaboration with many different 
specialists, professions and patient representatives, 
we have developed guidance statements for the 
investigation and management of adult iiH.
sCope
This is a consensus document to provide practical 
information for best practice in uniform investiga-
tion and treatment strategies based on current liter-
ature and opinion from a specialist interest group 
(SIG) for adult idiopathic intracranial hypertension 
(IIH). This should increase awareness of IIH among 
clinicians and improve outcomes for patients.
The target audience for this statement includes 
neurologists, ophthalmologists, neurosurgeons, 
radiologists, emergency medicine specialists, physi-
cians, ear nose and throat specialists and other 
clinicians who investigate and manage IIH. It also 
contains information that will be of interest to those 
in primary care and other healthcare professionals.
The increasing economic burden of IIH has been 
highlighted by a number of groups.1 2 Clear guid-
ance will help educate the attending doctors to 
manage these patients appropriately. This will help 
reduce the repeat unsolicited emergency hospital 
attendances and reduce IIH-related disability. 
There are a number of ongoing clinical trials in IIH 
(https://www. clinicaltrials. gov/) and as evidence for 
medical and surgical management evolves in IIH 
this document will require timely updates.
bACkGround
IIH occurs predominantly in women and although 
the underlying pathogenesis is not fully under-
stood, it has a striking association with obesity.3 
The combination of raised intracranial pressure, 
without hydrocephalus or mass lesion, normal cere-
brospinal fluid (CSF) composition and where no 
underlying aetiology is found are accepted criteria 
for the diagnosis of IIH.4 The overall age-adjusted 
and gender-adjusted annual incidence is increasing 
and was reported to be 2.4 per 100 000 within the 
last decade (2002–2014).5
The majority of patients presenting with IIH have 
symptoms that include a headache that is progres-
sively more severe and frequent, as defined by Inter-
national Classification of Headache Disorders, 3rd 
edition (ICHD-3) (figure 1).6 The headache pheno-
type is highly variable and may mimic other primary 
headache disorders. Other symptoms may include 
transient visual obscurations (unilateral or bilateral 
darkening of the vision typically seconds), pulsa-
tile tinnitus, back pain, dizziness, neck pain, visual 
blurring, cognitive disturbances, radicular pain and 
typically horizontal diplopia (figure 1A)3: none of 
which are pathognomonic for IIH.7 Investigation 
and management depends on symptoms and signs 
and requires an interdisciplinary team approach.
For the individual patient, some can have 
permanent visual loss.8 Chronic headache signifi-
cantly impacts quality of life9 10 with over half of 
patients with IIH reporting ongoing headaches at 
12 months.11
Clinical uncertainty exists, and IIH can be 
misdiagnosed.12 The 2015 Cochrane review has 
concluded that there is lack of evidence to guide 
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pharmacological treatment in IIH.13 Randomised clinical trials 
are currently infrequent in this field due to the rarity of the 
disease, the lack of understanding of the underlying patholog-
ical mechanisms and limited disease-modifying therapies.
MeThods
An SIG was formed, including neurology, neurosurgery, 
neuroradiology, ophthalmology, nursing, primary care doctors 
and patient representatives. All clinicians had expertise in 
managing IIH. An initial UK survey of attitudes and practice 
in IIH was sent to a wide group of consultants who investigate 
and manage IIH regularly: these included neurology, neuro-
surgery, neuro-ophthalmology and neuroradiology. A compre-
hensive systemic literature review was performed to assemble 
the foundations of the statements. Rigorous controlled data 
are sparse in IIH, and therefore, a consensus-based guide is 
presented. Questions were formulated (table 1). An anony-
mous modified Delphi process was used to obtain consensus on 
guidance statements. All statements below obtained consensus 
of 75% or above from the SIG and wider Delphi group. A 
completed AGREE statement is found as supplementary data 
(online supplementary appendix 1).
An international panel of experts in IIH (RHJ, GTL and KD) 
reviewed the document and a wider consultation was made with 
professional bodies namely the Association of British Neurol-
ogists (ABN), the Society of British Neurological Surgeons 
(SBNS), the Royal College of Ophthalmologists (RCOphth) 
and the British Association for the Study of Headache (BASH). 
Where there was disagreement in statement recommendations, 
these were debated within the SIG, and wording was altered 
accordingly.
Specifically, to improve local outcomes for patients with IIH, 
audit recommendations are enclosed (online supplementary 
appendix 2). This document will need to be revised regularly as 
new evidence emerges in the field of IIH. Definitions used in the 
guidance are presented in table 2.14–17
diAGnosTiC prinCiples
For optimal investigation of patients with papilloedema, there 
must be clear communication between clinicians for seamless 
joint investigation between the various specialities. The aims of 
investigations of papilloedema are to:
1. find any underlying treatable cause in a timely manner
2. protect the vision and ensure timely re-examination when 
vision is at risk
3. enable onward care of the patient with the input from the 
most appropriate experienced clinician.
Q1 how should papilloedema be investigated? (figure 2)
 ► Blood pressure must be measured to exclude malignant 
hypertension, as defined as a diastolic blood pressure greater 
Figure 1 Consensus in diagnosing iiH. (A) Frequency of iiH symptoms reported, adapted from Markey et al.3 (B) iiH diagnostic criteria, adapted 
from Friedman et al.4 (C) iiHwOP diagnostic criteria, adapted from Friedman et al.4 (D) Headache attributed to iiH, as described by the international 
Classification of Headache Disorders, 3rd edition (beta version) (iCHD-3 beta).6 (e) Line figure detailing the consensus of the interpretation of LP opening 
pressure. Uncertainty: it needs to be recognised that this is a single LP OP measurement; and after raised iCP what is then a normal iCP for this population 
on repeat LP readings is unknown. CSF, cerebrospinal fluid; iiH, idiopathic intracranial hypertension; LP, lumboperitoneal. 
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than or equal to 120 mm Hg or systolic blood pressure 
greater than or equal to 180 mm Hg.18
 ► Ophthalmology examination: all patients should have papil-
loedema confirmed and an assessment made of the immi-
nent risk to their visual function. The following should be 
recorded in the presence of papilloedema:
 – visual acuity
 – pupil examination
 – intraocular pressure (to exclude hypotony, a rare cause 
for disc swelling)
 – formal visual field test (perimetry)
 – dilated fundal examination to grade the severity of the 
papilloedema and exclude ocular causes for disc swelling.
Where possible, document the fundus picture with drawings 
and document key findings on the optic nerve head (hyperaemia, 
haemorrhages, cotton wool spots, obscuration of the vessels and 
so on). Photographs and/or optical coherence tomography (OCT) 
imaging are useful. Where visual function is found to be threat-
ened, regular ophthalmic examination must occur because this will 
influence timely management (see 23 How should we follow-up 
and monitor these patients? in table 3).
Uncertainty 
Where there is diagnostic uncertainty regarding papilloedema 
see the differential diagnosis of papilloedema and pseu-
dopapilloedema in supplementary table 1, an experienced 
clinician should be consulted early before invasive tests are 
performed. 
 
 ► Neurological examination
 – Record cranial nerve examination. Where IIH is suspect-
ed, typically there should be no cranial nerve involve-
ment other than sixth cranial nerve palsy/palsies.
 – Should other cranial nerves and/or other pathological 
findings be involved, an alternative diagnosis should be 
considered.
 ► Neuroimaging
 – Urgent MRI brain within 24 hours; if unavailable with-
in 24 hours, then urgent CT brain with subsequent MRI 
brain if no lesion identified.
 – There should be no evidence of hydrocephalus, mass, 
structural, vascular lesion and no abnormal meningeal 
enhancement.4
Table 1 Questions formulated by the ABN IIH SIG on the diagnosis 
and management of IIH
Question 
number
Diagnostic principles
1 How should papilloedema be investigated?
Management principles
Principle one: treat the underlying disease
2 What is the best way to modify the underlying disease to induce 
remission?
Principle two: protect the vision
3 How should IIH be treated when there is imminent risk of visual 
loss?
4 What is currently the best surgical procedure for visual loss in IIH?
5 What other surgical procedures are performed for visual loss in IIH?
6 What is the current role of neurovascular stenting in acute IIH to 
prevent loss of vision?
7 What is the role of serial lumbar punctures in IIH?
8 What is the best drug treatment for IIH symptoms?
9 How should acetazolamide be prescribed?
10 Are there other drugs that are helpful in IIH?
Principle three: manage the headache
11 What is the best way to manage headaches in newly diagnosed 
IIH? (figure 4)
12 What is the best approach to long-term headache management in 
IIH?
13 What therapeutic strategies are useful for headache in IIH?
14 How should medication overuse headache be approached?
15 Should CSF diversion surgery be used in patients with IIH with 
headache alone?
16 Should neurovascular stenting be used in patients with IIH with 
headache alone?
17 How should an acute exacerbation of headache be investigated in 
those who are already shunted?
18 How should an acute exacerbation of headache be treated in those 
who are already shunted?
Clinical care and managing IIH in pregnancy
19  Are there any other chronic problems that need to be addressed in 
IIH?
20 What advice should be given regarding drug treatments in the 
pregnant patient with IIH?
21 What additional considerations for management are there in the 
pregnant patient with IIH?
IIHWOP
22 How should IIHWOP be managed?
Follow-up and monitoring of IIH
23 How should we follow-up and monitor these patients?
ABN, Association of British Neurologists; CSF, cerebrospinal fluid; IIH, idiopathic 
intracranial hypertension; IIHWOP, IIH without papilloedema; SIG, specialist interest 
group.
Table 2 Definitions of the terms used in the guidance
Term definition
Adult All patients above the age of 16 years old for the 
purpose of this statement.
Idiopathic intracranial 
hypertension (IIH)
Patients with raised ICP of unknown aetiology 
fulfilling the criteria set out in figure 1.
Fulminant IIH Patients meeting the criteria for a precipitous decline 
in visual function within 4 weeks of diagnosis of IIH.14
Typical IIH Patients who are female, of childbearing age and who 
have a body mass index (BMI) greater than 30 kg/m2.
Atypical IIH Patients who are not female, or not of childbearing 
age or who have a BMI below 30 kg/m2. These 
patients require more in-depth investigation to ensure 
no other underlying causes (table 2).15 25
IIH without papilloedema A rare subtype of IIH16 17 and is seen in patients who 
meet all the criteria of definite IIH,4 seen in figure 1, 
in the absence of papilloedema. The criteria have 
highlighted the importance of a pressure greater than 
25 cm CSF and the necessity for additional features, 
which suggest pathologically raised ICP. Features 
such as sixth nerve palsy and MRI imaging features 
indicating raised ICP should be sought (box 1).
IIH in ocular remission Patients that have been diagnosed as IIH, and the 
papilloedema has resolved. These patients may have 
ongoing morbidity from headache, but their vision is 
no longer at risk while there is no papilloedema.
Experienced clinician Refers to any clinician, in the context of this guidance, 
who has confidence in their own experience of 
managing IIH.
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 – CT or MR venography is mandatory to exclude cerebral 
sinus thrombosis within 24 hours.
 – Characteristics of raised intracranial pressure may be 
seen on neuroimaging (box 1); these are not pathogno-
monic of IIH.19–22
Uncertainty
We recognise the difficulties in the interpretation of cerebral 
venography. Where there is diagnostic uncertainty regarding 
interpretation of the venogram findings , an experienced radiolo-
gist should be consulted.
 
 ► Lumbar puncture
 – Following normal imaging, all patients with papilloede-
ma should have a lumbar puncture to check opening 
pressure and ensure contents are normal.
 – The lumboperitoneal (LP) opening pressure should be 
measured in the lateral decubitus position.4 Following 
Figure 2 A flow diagram of investigation of papilloedema. BMi, body mass index; iiH, idiopathic intracranial hypertension.
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needle insertion into the CSF space, the pressure record-
ing should occur with the patient relaxed and the legs ex-
tended. The CSF level should be allowed to settle before 
taking the reading.
 – The CSF analysis should be tailored to the presentation 
but should at a minimum include CSF protein, glucose 
and cell count.
 – A clear explanation of the LP should be given to patients 
to reduce fear and anxiety about the procedure.
 – Where difficulty exists in performing the LP, the length 
of the procedure should be balanced by the comfort of 
the individual patient.
 – Should the LP not be successful, a guided LP could then 
be considered (ultrasound or X-ray).23 24
 – The diagnostic criteria mandate a cut-off opening pres-
sure of >25 cm CSF for diagnosing IIH.4
 – The LP opening pressure should not be interpreted in 
isolation when diagnosing IIH.
Uncertainties
Clinicians debate the absolute LP opening value of 25 cm CSF 
as diagnostic of IIH. This was recognised by Friedman and 
colleagues.4 Below the cut-off of 25 cm CSF, there are reser-
vations as to the likelihood of diagnosing IIH. As highlighted 
in figure 1E, the SIG clinicians’ opinions are that there is an 
increasing likelihood of the significance of LP OP measurement, 
as it rises. The LP OP is a single measurement, and it is widely 
recognised that there is a diurnal and wide variation in CSF 
pressure.
Where the LP OP does not fit the clinical picture, it should 
be interpreted with caution. A repeat LP may be considered 
or intracranial ICP monitoring could be considered. There 
is no current evidence to dictate how much CSF is recom-
mended to be drained or what the closing pressure should be. 
 
 ► Exclusion of all other secondary causes of raised ICP
 – All should have a careful history taken to exclude any 
possible secondary causes that have previously been 
linked to raised intracranial hypertension (table 2), al-
though the causal link with IIH and a number of diseases 
and medications is not clear.15 25
 – All patients should have a full blood count performed to 
exclude anaemia.26 27
 – Where patients are deemed to be atypical (table 1), other 
additional blood tests may be considered to exclude sec-
ondary causes.
 – Where patients are deemed to be atypical (table 1), ad-
ditional neuroimaging might be considered. These may 
include more proximal imaging of the neck vasculature 
to exclude internal jugular obstruction.
Uncertainty
In those with IIH, there is no clear evidence of a contraindi-
cation for using medications (including the oral contraceptive) 
that have been previously been reported to be casually associated 
with secondary pseudotumour.
Where uncertainty exists, patients who have atypical aspects 
could be referred for an opinion from a experienced clinician 
familiar with IIH.
MAnAGeMenT prinCiples
For optimal management of patients with IIH, there must be 
clear communication between clinicians for seamless joint care 
between the various specialties (figure 3). Weight loss reduces 
ICP and has been shown to be effective in improving papil-
loedema and headaches.28 The main principles of management 
of IIH are:
1.  to treat the underlying disease
2.  to protect the vision
3.  to minimise the headache morbidity.
Twenty-three questions were formulated to cover the three 
principle domains of management in IIH (table 1).
primary principle for iih management: modify the underlying 
disease through weight loss
Q2 What is the best way to modify the disease to induce remission?
Weight loss is the only disease-modifying therapy in typical 
IIH.28
 ► Once definite IIH is diagnosed, all patients with a 
BMI >30 kg/m2 should be counselled about weight manage-
ment at the earliest opportunity. This should be done with 
sensitivity.
Table 3 Associations that have been reported as causing raised 
Intracranial pressure15 25
haematological
Anaemia
polycythaemia vera
Obstruction to venous 
drainage
Cerebral venous sinus thrombosis
Jugular vein thrombosis
Superior vena cava syndrome
Jugular vein ligation following bilateral radical 
neck dissection
Increased right heart pressure
Arteriovenous fistulas
Previous infection or subarachnoid haemorrhage 
causing decreased CSF absorption 
Medications Fluoroquinolones
Tetracycline class antibiotics
Corticosteroid withdrawal
Danazol
Vitamin A derivatives (including isotretinoin and all-
transretinoic acid) 
Levothyroxine
Nalidixic acid
Tamoxifen
Ciclosporin
Levonorgestrel impant
Lithium
Growth hormone
Indomethacin
Cimetidine
Systemic disorders Chronic kidney disease/renal failure
Obstructive sleep apnoea syndrome
Chronic obstructive pulmonary disease
Systemic lupus erythematosus
Psittacosis
Endocrine Addison’s disease
Adrenal insufficiency
Cushing’s syndrome
Hypoparathyroidism
Hypothyroidism
Hyperthyroidism
Syndromic Down syndrome
Craniosynostosis
Turner syndrome
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 ► The amount of weight loss required to put the disease into 
remission is not known. It is noted that in the year preceding 
a diagnosis of IIH is associated with 5%–15% wt gain,29 and 
up to 15% of weight loss was required to put IIH into remis-
sion in one cohort.28
 ► Patients should be referred to a community weight manage-
ment programme or a hospital-based weight programme.
Uncertainty
Maintained weight loss is difficult to achieve, and the optimal 
approach to achieving long-term weight management has not yet 
been clearly established.30 31 If weight loss cannot be achieved 
by the patients themselves, the first step would be professional 
help through a structured diet. There is an increasing role for 
bariatric surgery for sustained weight loss,31 32 and for use in IIH, 
more prospective controlled evidence is required.2 33 34 For those 
who are not obese secondary causes should be revisited (box 1), 
and the role of weight gain/loss remains uncertain.
second principle for iih management: protect the vision
Q3 How should IIH be treated when there is imminent risk of visual 
loss?
 ► Where there is evidence of declining visual function, the 
acute management to preserve vision is surgical.
 ► A temporising measure of a lumbar drain could be useful to 
protect the vision while planning urgent surgical treatment.
 ► There is evidence that many of the surgical procedures, 
such as CSF diversion and optic nerve sheath fenestration 
(ONSF), work well in the short term.35 While they are 
working, the underlying disease should be modified with 
weight loss (see 1. What is the best way to modify the disease 
to induce remission? in table 3).
Uncertainty
In the absence of high class evidence, we do not recommend the 
use of corticosteroids for fulminant IIH at this time, and indeed 
a prolonged treatment course of corticosteroids would not be 
recommended due to weight gain.
Q4 What is currently the best surgical procedure for visual loss in 
IIH?
 ► In the UK, the preferred surgical procedure is neurosurgical 
CSF diversion (see 5. What other surgical procedures are 
performed for visual loss IIH?).
 ► Where possible. it should be performed by a experienced 
clinician with an interest in CSF disorders.
box 1 Typical neuroimaging features found in raised 
intracranial pressure19–22
Neuroimaging features of raised ICP:
 ► empty sella
 ► partially empty sella/decreased pituitary height
 ► increased tortuosity of optic nerve
 ► enlarged optic nerve sheath (perioptic subarachnoid space)
 ► flattened posterior globe/sclera
 ► intraocular protrusion of optic nerve head
 ► attenuation of the cerebrovenous sinuses including bilateral 
transverse sinus stenosis or stenosis of a dominant transverse 
sinus.
Note: Enhancement with IV contrast of the optic nerve sheath has been 
reported. Additionally, ventricle size in IIH is typically normal however 
many reports consider the ventricles to be slit-like. 
Figure 3 Management flow chart of diagnosed iiH. BMi, body mass index; CSF, cerebrospinal fluid; iiH, idiopathic intracranial hypertension.
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 ► Ventriculoperitoneal (VP) should be the preferred CSF 
diversion procedure for visual deterioration in IIH, due to 
lower reported revisions per patient.2
 ► An LP shunt could also be used.
 ► It is best practice to use neuronavigation to place VP shunts.
 ► All patients in the UK should be counselled that they should 
inform the Driver and Vehicle Licensing Agency following 
VP shunt placement.
 ► Adjustable valves with antigravity or antisiphon devices 
should be considered for use to reduce the risk of low pres-
sure headaches.
Uncertainty
The literature pertaining to shunt type is observational and 
mainly case series based. Complications of shunts include 
abdominal pain, shunt obstruction, migration and infection, low 
pressure headaches, subdural haematoma and tonsillar hernia-
tion.36 37 There is a low, but present, mortality rate with CSF 
diversion; these figures do not come from IIH cohorts.
Q5 What other surgical procedures are performed for visual loss in 
IIH?
ONSF is performed more frequently in Europe and the USA and 
rarely in the UK. ONSF is reported to have less complications 
than CSF diversion, and there have been no reports of mortal-
ities in the literature. The reported temporary adverse effects 
include double vision, ansiocoria and optic nerve head haemor-
rhages. Very rarely more permanent sequelae that include branch 
and central retinal artery occlusions have been reported. Some 
consider ONSF as the first treatment step in malignant fulmi-
nant cases and eventually also for those with asymmetric papil-
loedema causing visual loss in one eye.38 If this procedure fails, 
then the more invasive CSF diversion can be considered. ONSF 
should be performed by an experienced clinician trained in this 
technique.
Uncertainty
The literature is observational and mainly case series based.38 39 
Treatment failure rates include worsening in vision after a period 
of stabilisation in 34% of patients at 1 year and 45% at 3 years. 
There is also failure to improve headache in one third to 
one-half.39
Q6 What is the current role of neurovascular stenting in acute IIH to 
prevent loss of vision?
Improvements in venography imaging now detail that many with 
IIH have anatomical abnormalities of the cerebral venous sinus 
system. These include stenosis of the dominant or both trans-
verse sinus. The stenosis may result from intrinsic dural sinus 
anatomy or extrinsic compression by the increased intracranial 
pressure and reducing ICP can led to resolution of stenosis. The 
degree of stenosis does not appear to uniformly correlate with 
intracranial pressure or visual loss.40 Neurovascular stenting has 
been reported, in a number of series, to lead to an improvement 
in symptoms of intracranial hypertension. Complications of the 
procedure include a short-lived ipsilateral headache in many, 
stent-adjacent stenosis that require retreatment in a third and 
in rare cases vessel perforation leading to acute subdural haema-
toma, stent migration and thrombosis.
 ► The role of neurovascular stenting in IIH is not yet 
established.
 ► Long-term antithrombotic therapy is required for longer 
than 6 months following neurovascular stenting treatment.
Uncertainty
The literature is observational and mainly case series based, and 
there is no long-term data regarding efficacy and safety. The role 
of neurovascular stenting in IIH to preserve rapidly deteriorating 
vision is not yet established, as there is a lack of quality data in 
this area. It may be useful for highly selected patients with IIH 
with venous sinus stenosis with an elevated pressure gradient and 
elevated ICP in whom traditional therapies have not worked.40 41
Figure 4 Flow chart of acute exacerbation of headache in iiH with known CSF shunt in situ. CSF, cerebrospinal fluid; iiH, idiopathic intracranial 
hypertension. 
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Q7 What is the role of serial lumbar punctures in IIH?
The relief from a LP is typically short lived as CSF is secreted 
from the choroid plexus at a rate of 25 mL/hour and conse-
quently the volume removed in a so-called therapeutic tap is 
rapidly replaced.42
 ► Serial lumbar punctures are not recommended for manage-
ment of IIH.
 ► Despite the relief of headache in nearly three quarters of 
patients,43 LPs are associated with significant anxiety in 
many patients and can led to acute and chronic back pain in 
some patients.7 43
 Q8 What is the best drug treatment for IIH symptoms?
The current Cochrane review on IIH management reported on 
the use of acetazolamide, a carbonic anhydrase inhibitor, in IIH. 
It concluded: ‘the two included RCTs showed modest bene-
fits for acetazolamide for some outcomes, there is insufficient 
evidence to recommend or reject the efficacy of this interven-
tion, or any other treatments currently available, for treating 
people with IIH’.13
The two studies included in this review were:
a. The IIH Treatment Trial44 reported the use of acetazolamide 
with a low-sodium weight-reduction diet compared with diet 
alone resulted in modest improvement in visual field func-
tion in patients with mild visual loss. The IIHTT also re-
ported improved quality of life outcomes at 6 months with 
acetazolamide.45
b. Ball et al46 failed to show a treatment effect. Importantly, 
48% discontinued acetazolamide due to adverse effects.
 ► Acetazolamide could be prescribed for those with IIH 
symptoms.
 ► All females with IIH when commencing any new medical 
therapy (whether IIH specific or headache related) must be 
counselled regarding side effects and potential teratogenetic 
risks (see 21. What additional considerations for manage-
ment are there in the pregnant patient with IIH? in table 3).
 ► Drug therapies may need to be altered due to adverse side 
effects, lack of efficacy, possible potential teratogenic effects 
in pregnancy or patient preference.
Uncertainty
In view of the limited evidence as reported by the 2015 Cochrane 
review13 and the side effect profile, not all clinicians in the UK 
prescribe acetazolamide for IIH.
Q9 How should acetazolamide be prescribed?
 ► The IIHTT used a maximal dose of 4 g daily, with 44% of 
participants achieving 4 g/day, and the majority tolerating 
1 g/day.47 Ball et al46 identified that 48% discontinued at 
mean doses of 1.5 g due to side effects.
 ► A popular starting dose of acetazolamide is 250–500 mg 
twice a day, with the majority of clinicians titrating the daily 
dose up.
 ► Patients should be warned of the adverse side effects of 
acetazolamide that are well recognised and include increased 
risk of diarrhoea, dysgeusia, fatigue, nausea, paraesthesia, 
tinnitus, vomiting, depression and rarely renal stones.
 ► There is no consensus over the use of normal release and 
modified release acetazolamide.
Uncertainties
The optimal dose of acetazolamide is not established. The 
licencing information regarding acetazolamide recommends 
periodic monitoring of serum electrolytes; however, there is no 
consensus on the timing of monitoring.
Q10 Are there other drugs that are helpful in IIH?
Topiramate has carbonic anhydrase activity and can suppress 
appetite. It has been compared with acetazolamide in an uncon-
trolled open label study for IIH.48 Participants were alternately 
assigned to the treatments, not randomly, and there was no 
placebo control group. There is evidence of efficacy of topira-
mate in treating migraine.49
 ► There may be a role for topiramate in IIH with weekly dose 
escalation from 25 mg to 50 mg bd.
 ► Where topiramate is prescribed, women must be informed 
that it can reduce the efficacy of the contraceptive pill/oral 
contraceptives and other hormonal contraceptives.
 ► When topiramate is prescribed, women must be counselled 
regarding side effects (including depression and cognitive 
slowing) and potential teratogenetic risks.
Uncertainties
The role of other diuretics such as furosemide, amiloride and coam-
ilofruse are not certain but are used by some as alternative therapies.
Third principle of iih management: reduce headache 
disability
Raised ICP can drive headaches, which may be very severe at 
presentation.11 Despite significant headache morbidity in IIH, 
there are no randomised controlled trials to guide headache 
management in IIH.
Q11 What is the best way to manage headaches in newly diagnosed 
IIH?
 ► Patients must be informed, at the earliest opportunity, of the 
potential issues of painkiller overuse that can lead to medi-
cation overuse headache (use of simple analgesics on more 
than 15 days per month or opioids, combined preparations 
or triptan medication on greater than 10 days per month for 
more than 3 months).6
 ► Short-term painkillers may be helpful in the first few 
weeks following diagnosis. These could include non-ste-
roidal anti-inflammatory drugs (NSAIDs) or paracetamol. 
Indomethacin may have some advantage due to its effect 
of reducing ICP.50 Caution is required with potential side 
effects of NSAIDs, and gastric protection may be needed.
 ► Opioids should not be prescribed for headaches.51
 ► Greater occipital nerve blocks maybe considered helpful by 
some, but there is a lack of evidence and consensus.
 ► Acetazolamide has not been shown to be effective for the 
treatment of headache alone.
 ► Lumbar punctures are not typically recommended for treat-
ment of headache in IIH (see 7. What is the role of serial 
lumbar punctures in IIH? in table 3).
Uncertainty
There is no evidence to support the optimal managing of head-
ache in acute IIH.
Q12 What is the best approach for long-term headache 
management in IIH?
The pattern of headache in IIH often changes over time and 
needs careful assessment. There is frequently a mixed headache 
phenotype: headache attributed to IIH, migraine, medication 
overuse headache, tension-type headache, headache attributed 
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to low CSF pressure and headache attributed to iatrogenic 
Chiari malformation secondary to CSF shunting.52 53
 ► A multidisciplinary team approach could be considered 
including, ideally, an assessment by an experienced clinician 
with an interest in headache management.
 ► In patients with IIH, the headache phenotype should be 
assessed. Headache therapies should be tailored to the head-
ache phenotype.
 ► IIH patients with headache need clear explanation of how 
their headaches change over time and how to minimise the 
risks of developing medication overuse headache.
 ► Early introduction of preventative medications (migraine 
preventatives) should be considered as these can take 3–4 
months to reach maximal efficacy.
Uncertainty
There is no evidence to support the optimal managing of head-
ache in established IIH.
Q13 What therapeutic strategies are useful for headache in IIH?
Migrainous phenotype is noted in 68% of IIH patients with 
headache.54 Despite the lack of clinical trials, the use of migraine 
therapies in IIH patients with migraine headaches may be useful. 
Headaches with migrainous features include moderate to severe 
pain that maybe throbbing with photophobia, phonophobia, 
nausea and movement intolerance.
 ► Migraine attacks may benefit from triptan acute therapy 
used in combination with either a NSAID or paracetamol 
and an antiemetic with prokinetic properties.51 Their use 
should be limited to 2 days per week or a maximum of 10 
days per month.55 56
 ► Migraine preventative strategies could also be tried. These 
are most likely to be effective in those in whom the ICP 
is settling and also in those whom the papilloedema has 
resolved (IIH in ocular remission).
 ► National Institute of Health and Clinical Excellence guide-
lines for migraine prevention therapy is useful.51
 ► Caution must be observed before selecting drugs that could 
increase weight (beta blockers, tricyclic antidepressants, 
sodium valproate, pizotifen and flunarizine) or those that 
could exacerbate depression, a frequent comorbidity in IIH 
(beta blockers, topiramate and flunarizine).
 ► Topiramate (see 10. Are there other drugs that are helpful in 
IIH? in table 3) may help with weight loss by suppressing 
appetite and have an effect on reducing ICP through 
carbonic anhydrase inhibition. Patients need to be cautioned 
about potential side effects of depression, cognitive slowing, 
reduction of the efficacy of the contraceptive pill/oral 
contraceptives and potential of teratogenic effects.
 ► Where topiramate has excessive side effects, zonisamide may 
be an alternative.49
 ► In patients with migraine, candesartan can be a useful alter-
native to a beta blocker due to its lack of weight gain and 
depressive side effects.57 Alternatively, venlafaxine is weight 
neutral and helpful with depression symptoms.58
 ► Botulinum toxin A may be useful in those with coexisting 
chronic migraine59; there are no studies of botulinum toxin 
A in IIH.
 ► As with treatment of migraine, preventative drugs need to be 
started slowly and increased to a therapeutic tolerated dose 
for 3 months to enable a therapeutic trial.
 ► Similar to the treatment of migraine, many of these drugs are 
used off label in IIH.
 ► Lifestyle advice should be given with all headache disor-
ders, as these can have considerable impact on the disease 
course. Strategies should be implemented to limit caffeine 
intake. Ensure regular meals and adequate hydration, exer-
cise programme and sleep hygiene. Behavioural and stress 
management techniques can be implemented such as yoga, 
cognitive–behavioural therapy and mindfulness.
Uncertainty
There are no clinical trials as yet in the treatment of headache 
alone in IIH.
Q14 How should medication overuse be approached?
Medication overuse is a common issue for patients with IIH.11 
Successfully removing excessive analgesic use significantly 
improves headaches.60 Additionally, if not addressed, MOH 
may prevent the optimisation and effectiveness of preventative 
treatments.
 ► Non-opioids and triptan medications may be stopped 
abruptly or weaned down within a month.60
 ► Opioid medications should be gradually removed, with at 
least 1 month painkiller free to determine effectiveness61
Uncertainty 
The most effective strategies to facilitate acute analgesic medica-
tion withdrawal are not fully established.56
Q15 Should CSF diversion surgery be used in patients with IIH with 
headache alone?
Where papilloedema has resolved, typically, the ICP will be 
normalising, and conservative treatment strategies should be 
employed. CSF shunting to exclusively treat headache in IIH has 
limited evidence. Following CSF diversion 68% will continue to 
have headaches at 6 months and 79% by 2 years.36 Twenty-eight 
per cent can develop iatrogenic low pressure headaches,36 
although this figure will vary depending on shunt and valve type.
 ► CSF diversion is generally not recommended as a treatment 
for headache alone in IIH.
 ► CSF diversion procedures for the management of headaches 
should only be carried out in a multidisciplinary setting and 
following a period of intracranial pressure monitoring.
Uncertainty
Patients with IIH often have coexisting migrainous headaches 
superimposed on the headaches secondary to raised intracranial 
pressure. Failure to optimise the ICP may render the migrainous 
headache difficult to treat.
Q16 Should neurovascular stenting be used in patients with IIH with 
headache alone?
The literature detailing stenting typically does not clearly sepa-
rate the cohorts of IIH into those with visual loss, those with 
headaches alone and those with both. They typically also do 
not separate those with acute IIH, those with chronic IIH and 
those with IIH in ocular remission. Another major limitation is 
that case series are non-randomised; typically, they do not detail 
morphological stenosis type; they tend to be small in size with 
selection bias, and there is a lack of long-term follow-up.62
 ► Neurovascular stenting is not currently a treatment for head-
ache in IIH.
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Uncertainty
Patients with IIH often develop migrainous headaches superim-
posed on the headaches secondary to raised intracranial pres-
sure. While CSF diversion procedures have not been shown 
to be effective for the management of headaches, this may be 
attributable to the migrainous component not being optimally 
addressed. Conversely, failure to optimise the ICP (with a CSF 
diversion procedures) may render the migrainous headache 
difficult to treat. CSF diversion procedures for the manage-
ment of headaches should only be carried out in a multidisci-
plinary setting and following a period of intracranial pressure 
monitoring.
Management of headaches in the shunted patient with iih
Shunted patients with IIH may have significant headache 
morbidity, and shunt failures and overdrainage should always 
be considered. Understanding the underlying causes may guide 
management. Shunt revision should not routinely be undertaken 
unless there is papilloedema and a risk of visual deterioration. 
Many of these patients may be in ocular remission, as with 
chronic IIH headaches, conservative management with migraine 
therapies and treatment of medication overuse should be tried 
initially. Patients may need assessment by a experienced clini-
cian who routinely manage headache. Medication refractory 
patients should be managed in a specialist headache service and 
discussed within a multidisciplinary setting for consideration of 
ICP monitoring.
Q17 How should an acute exacerbation of headache be investigated 
in those who are already shunted? (figure 4) 
 ► For all shunted patient with IIH presenting with an acute 
exacerbation of headaches,funduscopy is mandatory to 
establish if papilloedema exists and where visual function 
(including formal visual fields) is documented to be wors-
ening, then surgical intervention may be required. For those 
with atrophic optic nerves further care should be taken to 
establish whether the headache is secondary to raised intrac-
ranial pressure.
 ► In those where there is suspicion of infection that may be 
worsening the headache, CSF should be obtained for micro-
biological evaluation and any underlying resultant infection 
appropriately treated.
 ► A diagnostic lumbar puncture should not be routinely 
performed in the absence of papilloedema (unless suspicion 
of infection, see above)
 ► In those with papilloedema, some may choose to perform a 
diagnostic LP. This may be helpful to establish ICP level and 
may have implications for management choices.
 ► CT imaging and shunt X-ray series should not routinely be 
considered for those without evidence of papilloedema, as 
these investigations do not alter management.63 64
 ► In some ICP, monitoring may be useful.
Q18 How should an acute exacerbation of headache be treated in 
those who are already shunted? (figure 4)
 ► For patients without current papilloedema or imminent risk 
to vision, shunt revision is not recommended.
 ► In shunted patients with deteriorating headaches, low pres-
sure headache and shunt over drainage should be considered.
 ► In established overdrainage or low CSF pressure, considera-
tion should be given to the valve settings or tying the shunt 
off.
 ► In the absence of shunt over drainage headache manage-
ment should follow the section above (see 13. What ther-
apeutic strategies are useful for headache in IIH? in table 3 
and figure 4: Manging acute exacerbation of headache in 
IIH).
 ► Consider medication overuse headache as a cause of acute 
exacerbation in shunted patients.65
Clinical care
Q 19 Are there any other chronic problems that need to be 
addressed in IIH?
 ► All of these patients require recognition that they have 
been diagnosed with a rare disease and need appropriate 
support to deal with the psychological burden of living with 
a chronic condition.
 ► The patient with IIH may have significantly higher levels of 
anxiety and depression and a lower quality of life.9 45 66 This 
may be as a response to chronic pain. This needs recognition 
and appropriate management.
 ► Sleep apnoea is frequently reported in this group,67 and 
referral to respiratory service may be appropriate.
 ► Polycystic ovary syndrome may coexist.68
 ► Cognitive dysfunction may coexist.69
Managing iih in pregnancy
Q20 What advice should be given regarding drug treatments in the 
pregnant patients with IIH?
 ► A clear risk−benefit assessment regarding the necessity 
of acetazolamide treatment during pregnancy should be 
discussed with the patient as perinatal exposure in rodents 
has reported teratogenic effects.70 71
 ► With the limited evidence, it is difficult to make any safe 
recommendations on using acetazolamide during pregnancy 
and its manufacturers do not recommend it use.72
 ► Topiramate should not be used in pregnancy. There is clear 
evidence of a higher rate of fetal abnormalities following its 
use.73
 ► If a patient on topiramate becomes pregnant, they should 
reduce and discontinue it as soon as possible in line with 
manufacturers recommendations.
 ► A clear risk−benefit assessment regarding the necessity of 
headache treatment during pregnancy should be discussed 
with the patient as many of the regularly used headache 
medications are not recommended in pregnancy.
Table 4 Consensus of follow-up intervals for patients with idiopathic 
intracranial hypertension (IIH) based on their papilloedema grade and 
their visual field status
papilloedema 
grade normal
Visual field status 
Affected but 
improving
Affected but 
stable
Affected but 
worsening
Atrophic 4–6 months Within 4 weeks
Mild 6 months 3–6 months 3–4 months Within 4 weeks
Moderate 3–4 months 1–3 months 1–3 months Within 2 weeks
Severe 1–3 months Within 
4 weeks
With 1 week
Note: Once papillodema has resolved, visual monitoring within the hospital 
services may no longer be required. However, caution in those patients who were 
asymptomatic at presentation, as they will likely be asymptomatic if a recurrence 
occurs and longer term follow-up, may need to be considered. 
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Q21 What additional considerations for management are there in 
the pregnant patient with IIH?
 ► Multidisciplinary communication among relevant experi-
enced clinicians should occur throughout pregnancy, peride-
livery and in the postpartum period.
 ► No specific mode of delivery should be suggested based on 
the fact there is a previous diagnosis of IIH.
 ► If not already under a weight management programme, 
consider referral to a weight service, so that weight gain is 
appropriate for gestational age of fetus as described by the 
American College of Obstetricians and Gynaecologists 2013 
Guidelines.74
 ► Increased outpatient observation may be helpful to reas-
sure other healthcare professionals and patients during this 
period.
 ► How should an acute exacerbation of IIH, with imminent 
risk to vision be managed in pregnancy?
 ► If the IIH is active with imminent risk of vision loss, then 
some would consider serial lumbar punctures as a tempo-
rising measure only until longer term measures, such as CSF 
diversion or ONSF, can be implemented.
 ► Those with imminent risk of vision loss at time of delivery 
should be managed in a specialist centre.
iih without papilloedema
Q22 How should IIHWOP be managed?
In patients with IIHWOP, risk of vision loss has not been identi-
fied and does not seem to develop over the disease course. Visual 
phenomenon such as photopsia, diplopia (from sixth nerve 
palsy) and functional visual field loss are common.75
Headache is the principal morbidity in these patients.
 ► Once definite IIHWOP is diagnosed, all patients should be 
managed as typical IIH and counselled about weight manage-
ment (see 2. What is the best way to modify the disease to 
induce remission? in table 3).
 ► Management of headache should be the same as typical IIH 
(see: Third principle of IIH management: reduce headache 
disability).
 ► Surgical management to control elevated intracranial pres-
sures in IIHWOP should not routinely be considered unless 
advised by experienced clinicians within the multidiscipli-
nary team setting.
Follow-up and monitoring of iih
Q23 How should we follow-up and monitor these patients?
Any patient with papilloedema should have the following 
documented24:
1. visual acuity
2. pupil examination
3. formal visual field assessment
4. dilated fundal examination to grade the papilloedema.
5. BMI calculation.
 – Formal documentation of the optic nerve head appear-
ance, such as serial photographs or OCT imaging, is use-
ful. There are increasing reports of the utility of transor-
bital ultrasound to measure optic nerve sheath diameter; 
however, there are considerable differences across studies 
on the cut-off values used as well as the efficacy of ultra-
sound to predict ICP.76
 – All patients with or without papilloedema should have an 
assessment of their headache to include the features of the 
headache/s (to aide characterisation of the headache), head-
ache frequency and severity and frequency of analgesic use.
 – A validated headache disability score such as HIT 6 may 
be useful.
 – Recommendations for follow-up intervals is seen at ta-
ble 4. Should there be worsening of the visual fields or 
papilloedema, then outpatient review should be expedit-
ed.
ClosinG sTATeMenT
In collaboration with many different experienced clinicians, 
professions and patient representatives, we have developed 
guidance statements for the investigation and management of 
adult IIH. We recognise that we were limited by the lack of high-
quality evidence for the majority of the statements made and 
that a consensus-based approach could give authority to singular 
opinion. With a view to mitigate this, we have sought interna-
tional expert review (GTL, RHJ and KD) and review by profes-
sional bodies (ABN, BASH, RCOphth and SBNS). Following 
review, a few points were upheld by the SIG such as the defini-
tion of typical IIH being diagnosed as obese and not just over-
weight (BMI >25 kg/m2), which differs from current published 
diagnostic criteria.4 As this document is aimed at a wide audi-
ence including non-IIH specialist, we wished to create criteria 
whereby the majority of patients with IIH would be correctly 
diagnosed. Hence, we needed to emphasise those patients in 
whom uncertainty could exist and referral to an experienced 
clinician maybe required. It was also highlighted that compared 
with our European and North American colleagues, there are 
few centres in the UK that perform ONSF for IIH.
These statements are not mandatory recommendations but are 
intended to be used as a guide for doctors who investigate and 
treat IIH. Despite the limitations of consensus-based methods, 
these statements reflect an up-to-date consensus to guide the 
clinician and serve our patients. Quality prospective research is 
required for all areas of uncertainties highlighted in this docu-
ment to improve clinical outcomes for our patients with IIH.
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